GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Operating Income

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Operating Income : $ Mil (TTM As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Operating Income?

CERo Therapeutics Holdings's Operating Income for the six months ended in Dec. 2022 was $-11.97 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. CERo Therapeutics Holdings's Operating Income for the six months ended in Dec. 2022 was $-11.97 Mil. CERo Therapeutics Holdings's Revenue for the six months ended in Dec. 2022 was $0.00 Mil. Therefore, CERo Therapeutics Holdings's Operating Margin % for the quarter that ended in Dec. 2022 was %.

CERo Therapeutics Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CERo Therapeutics Holdings's annualized ROC % for the quarter that ended in Dec. 2022 was -218.33%. CERo Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -268.26%.


CERo Therapeutics Holdings Operating Income Historical Data

The historical data trend for CERo Therapeutics Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Operating Income Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Operating Income
-11.62 -11.97

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Operating Income -11.62 -11.97

CERo Therapeutics Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CERo Therapeutics Holdings's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:

ROC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-11.971 * ( 1 - 0% )/( (6.001 + 4.965)/ 2 )
=-11.971/5.483
=-218.33 %

where

Note: The Operating Income data used here is one times the annual (Dec. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

CERo Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2021  Q: Dec. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.971/( ( (4.652 + max(-0.946, 0)) + (4.273 + max(-0.236, 0)) )/ 2 )
=-11.971/( ( 4.652 + 4.273 )/ 2 )
=-11.971/4.4625
=-268.26 %

where Working Capital is:

Working Capital(Q: Dec. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.307) - (0.489 + 0 + 0.764)
=-0.946

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.256) - (0.472 + 0 + 0.02)
=-0.236

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2022) EBIT data.

3. Operating Income is also linked to Operating Margin %:

CERo Therapeutics Holdings's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-11.971/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


CERo Therapeutics Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines